AstraZeneca Financial Statements From 2010 to 2025
| AZNCF Stock | USD 155.65 4.44 2.94% |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as , as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca |
AstraZeneca PLC Company Current Valuation Analysis
AstraZeneca PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AstraZeneca PLC Current Valuation | 241.1 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AstraZeneca PLC has a Current Valuation of 241.1 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is significantly lower than that of the firm.
AstraZeneca PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.62 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 1.63 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.About AstraZeneca PLC Financial Statements
AstraZeneca PLC stakeholders use historical fundamental indicators, such as AstraZeneca PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in AstraZeneca PLC's assets and liabilities are reflected in the revenues and expenses on AstraZeneca PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.